NasdaqGS:XRAY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental products and technologies, and other consumable dental products and equipment primarily for the professional dental market worldwide. More Details

Rewards

Trading at 34.4% below our estimate of its fair value

Earnings are forecast to grow 86.87% per year

Risk Analysis

No risks detected for XRAY from our risk checks.


Snowflake Analysis

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has DENTSPLY SIRONA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XRAY has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.2%

XRAY

-1.1%

US Medical Equipment

-1.4%

US Market


1 Year Return

-16.0%

XRAY

23.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: XRAY underperformed the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: XRAY underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

XRAYIndustryMarket
7 Day0.2%-1.1%-1.4%
30 Day2.1%5.2%4.7%
90 Day3.8%6.7%8.2%
1 Year-15.3%-16.0%24.8%23.8%20.5%17.8%
3 Year-23.3%-25.1%73.9%69.4%42.2%32.7%
5 Year-20.2%-22.9%145.2%126.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is DENTSPLY SIRONA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DENTSPLY SIRONA undervalued compared to its fair value and its price relative to the market?

34.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XRAY ($45.67) is trading below our estimate of fair value ($69.64)

Significantly Below Fair Value: XRAY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XRAY is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: XRAY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XRAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XRAY is good value based on its PB Ratio (2.1x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is DENTSPLY SIRONA forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

86.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: XRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XRAY's is expected to become profitable in the next 3 years.

Revenue vs Market: XRAY's revenue (8.7% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: XRAY's revenue (8.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XRAY's Return on Equity is forecast to be low in 3 years time (9.9%).


Next Steps

Past Performance

How has DENTSPLY SIRONA performed over the past 5 years?

-23.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XRAY is currently unprofitable.

Growing Profit Margin: XRAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XRAY is unprofitable, and losses have increased over the past 5 years at a rate of 23.6% per year.

Accelerating Growth: Unable to compare XRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).


Return on Equity

High ROE: XRAY has a negative Return on Equity (-1.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is DENTSPLY SIRONA's financial position?


Financial Position Analysis

Short Term Liabilities: XRAY's short term assets ($2.4B) exceed its short term liabilities ($763.0M).

Long Term Liabilities: XRAY's short term assets ($2.4B) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: XRAY's debt to equity ratio (47%) is considered high.

Reducing Debt: XRAY's debt to equity ratio has reduced from 51.8% to 47% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable XRAY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: XRAY is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 0.7% per year.


Next Steps

Dividend

What is DENTSPLY SIRONA current dividend yield, its reliability and sustainability?

0.88%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: XRAY's dividend (0.88%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.64%).

High Dividend: XRAY's dividend (0.88%) is low compared to the top 25% of dividend payers in the US market (4.68%).


Stability and Growth of Payments

Stable Dividend: XRAY's dividends per share have been stable in the past 10 years.

Growing Dividend: XRAY's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: XRAY is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: XRAY's dividends in 3 years are forecast to be thoroughly covered by earnings (14.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Don Casey (60 yo)

2.67yrs

Tenure

US$11,366,243

Compensation

Mr. Donald M. Casey, Jr., also known as Don, serves as CEO and Director at DENTSPLY International Inc., since 2018. Mr. Casey has been Chief Executive Officer and a Director at Dentsply Sirona Inc. since ...


CEO Compensation Analysis

Compensation vs Market: Don's total compensation ($USD11.37M) is about average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Don's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Donald Casey
CEO & Director2.67yrsUS$11.37m0.045%
$ 4.5m
Jorge Gomez
Executive VP & CFO1.17yrsUS$10.30m0.016%
$ 1.6m
Keith Ebling
Executive VP3yrsUS$4.61m0.0037%
$ 372.2k
Walter Petersohn
Senior VP & Chief Commercial Officer3.25yrsUS$3.11m0.020%
$ 2.0m
Ranjit Chadha
Chief Accounting Officer0.17yrno datano data
Cord Staehler
Senior VP & Chief Technology Officer1.42yrsno data0.0018%
$ 174.6k
John Sweeney
Vice President of Investor Relationsno datano datano data
Lisa Yankie
Senior VP and Chief HR Officer & Communications1yrno data0.0017%
$ 167.6k
Chidam Chidambaram
Senior VP1.42yrsno data0.0051%
$ 507.9k
Albert Sterkenburg
Senior Vice President11.75yrsUS$1.35mno data
Teresa Dolan
Chief Clinical Officer & VPno datano datano data
Markus Boehringer
Senior Vice President of EMEA RCO3.25yrsUS$1.52m0.012%
$ 1.2m

2.0yrs

Average Tenure

52.5yo

Average Age

Experienced Management: XRAY's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Donald Casey
CEO & Director2.67yrsUS$11.37m0.045%
$ 4.5m
Francis Lunger
Independent Director15.42yrsUS$326.95k0.012%
$ 1.2m
Eric Brandt
Independent Non-Executive Chairman3.08yrsUS$517.03k0.013%
$ 1.3m
Clyde Hosein
Director0.083yrno datano data
Harry M. Kraemer
Independent Director4.67yrsUS$278.57k0.059%
$ 5.9m
Betsy Holden
Independent Director2.75yrsUS$321.32k0.0042%
$ 423.1k
Michael Alfano
Independent Director19.67yrsUS$271.25k0.0050%
$ 497.9k
Leslie Varon
Independent Director2.75yrsUS$278.75k0%
$ 0
Gregory Lucier
Independent Director1.42yrsUS$256.42k0.0061%
$ 607.7k
Arthur Kowaloff
Independent Director4.67yrsUS$267.50k0.019%
$ 1.9m
William Deese
Independent Director9.67yrsUS$283.75k0.0069%
$ 693.5k
Janet Vergis
Independent Director1.08yrsUS$162.13kno data

2.9yrs

Average Tenure

63.5yo

Average Age

Experienced Board: XRAY's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DENTSPLY SIRONA Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DENTSPLY SIRONA Inc.
  • Ticker: XRAY
  • Exchange: NasdaqGS
  • Founded: 1899
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$9.979b
  • Shares outstanding: 218.50m
  • Website: https://www.dentsplysirona.com

Number of Employees


Location

  • DENTSPLY SIRONA Inc.
  • 13320 Ballantyne Corporate Place
  • Charlotte
  • North Carolina
  • 28277-3607
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XRAYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1987
DY2DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1987
0I8FLSE (London Stock Exchange)YesCommon StockGBUSDAug 1987
XRAYWBAG (Wiener Boerse AG)YesCommon StockATEURAug 1987
DY2ETLX (Eurotlx)YesCommon StockITEURAug 1987
XRAY34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REP 1 COM USD0.01BRBRLMay 2019

Biography

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental products and technologies, and other consumable dental products and equipment primarily for the professional dental market w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 23:33
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.